Localization of the Active Site of Human Tumour Necrosis Factor (hTNF) by Mutational Analysis

Overview

Journal EMBO J

Specialties Biotechnology
Molecular Biology

Date 1991 Apr 1

PMID 2009860

Citations 22

Authors

X Van Ostade

J Tavernier

T Prange

W Fiers

Affiliations

Soon will be listed here.

Abstract

In order to define the active site(s) of human tumour necrosis factor (hTNF), we mutagenized its gene at random and directly screened the resulting population for loss of cytotoxic activity on L929 cells. Four biologically inactive mutant proteins (Arg32----Trp, Leu36----Phe, Ser86----Phe and Ala84----Val) behaved similar to the wild-type in various physico-chemical assays. The residues were positioned on a 3D structural model and were found to cluster together at the base of the molecule at each side of the groove that separates two monomers in the trimeric structure. A very conservative mutation at one of these sites (Ala84----Val) almost completely abolished cytotoxic activity. Amino acid alterations in three other residues in close proximity to this receptor binding site were introduced: replacements at positions 29 and 146 clearly reduced cytotoxicity only when non-conservative alterations were introduced (Leu29----Ser and Glu146----Lys), suggesting an indirect influence on the active site. However, a conservative mutation at position 91 (Val----Ala) caused a significant drop (500-fold) in bioactivity which suggests that Val91 may also play a direct role in receptor recognition. Our results favor a model in which each TNF molecule has three receptor-interaction sites (between the three subunits), thus allowing signal transmission by receptor clustering.

Citing Articles

Biochemical evaluation of novel thiazolone derivatives as dual α-glucosidase/α-amylase inhibitors, anti-inflammatory agents.

Abdelhamid M, Eraky S, El-Deen I, Elian Sophy M Future Med Chem. 2025; 17(2):209-219.

PMID: 39829378 PMC: 11749350. DOI: 10.1080/17568919.2024.2447225.

Bioinspired gelatin based sticky hydrogel for diverse surfaces in burn wound care.

George B, Bhatia N, Kumar A, A G, R T, S K S Sci Rep. 2022; 12(1):13735.

PMID: 35962001 PMC: 9374690. DOI: 10.1038/s41598-022-17054-w.

Tumor necrosis factor alpha delivers exogenous inflammation-related microRNAs to recipient cells with functional targeting capabilities.

Zhao Y, Zhang T, Shen X, Huang A, Li H, Wang L Mol Ther. 2022; 30(9):3052-3065.

PMID: 35791880 PMC: 9481991. DOI: 10.1016/j.ymthe.2022.06.017.

Effects of theaflavin-gallate binding with different proteins of SARS-CoV-2 and host inflammation and vasoregulations referring an experimental rat-lung injury.

Maiti S, Banerjee A, Kanwar M Phytomed Plus. 2022; 2(2):100237.

PMID: 35403090 PMC: 8820952. DOI: 10.1016/j.phyplu.2022.100237.

Receptor Specificity Engineering of TNF Superfamily Ligands.

Suo F, Zhou X, Setroikromo R, Quax W Pharmaceutics. 2022; 14(1).

PMID: 35057080 PMC: 8781899. DOI: 10.3390/pharmaceutics14010181.

References

Hohmann H, Remy R, Brockhaus M, van Loon A . Two different cell types have different major receptors for human tumor necrosis factor (TNF alpha). J Biol Chem. 1989; 264(25):14927-34. View

Yamamoto R, Wang A, Vitt C, Lin L . Histidine-15: an important role in the cytotoxic activity of human tumor necrosis factor. Protein Eng. 1989; 2(7):553-8. DOI: 10.1093/protein/2.7.553. View

Tavernier J, Van Ostade X, Hauquier G, Prange T, Lasters I, De Maeyer M . Conserved residues of tumour necrosis factor and lymphotoxin constitute the framework of the trimeric structure. FEBS Lett. 1989; 257(2):315-8. DOI: 10.1016/0014-5793(89)81560-1. View

Engelmann H, Novick D, Wallach D . Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem. 1990; 265(3):1531-6. View

Espevik T, Brockhaus M, Loetscher H, Nonstad U, Shalaby R . Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor. J Exp Med. 1990; 171(2):415-26. PMC: 2187730. DOI: 10.1084/jem.171.2.415. View

Tavernier J, Marmenout A, Bauden R, Hauquier G, Van Ostade X, Fiers W . Analysis of the structure-function relationship of tumour necrosis factor. Human/mouse chimeric TNF proteins: general properties and epitope analysis. J Mol Biol. 1990; 211(2):493-501. DOI: 10.1016/0022-2836(90)90367-U. View

Brockhaus M, Schoenfeld H, Schlaeger E, Hunziker W, LESSLAUER W, Loetscher H . Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A. 1990; 87(8):3127-31. PMC: 53847. DOI: 10.1073/pnas.87.8.3127. View

Loetscher H, Pan Y, Lahm H, Gentz R, Brockhaus M, Tabuchi H . Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell. 1990; 61(2):351-9. DOI: 10.1016/0092-8674(90)90815-v. View

Schall T, Lewis M, Koller K, Lee A, Rice G, Wong G . Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell. 1990; 61(2):361-70. DOI: 10.1016/0092-8674(90)90816-w. View

10.

Smith C, Davis T, Anderson D, Solam L, Beckmann M, Jerzy R . A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science. 1990; 248(4958):1019-23. DOI: 10.1126/science.2160731. View

11.

Yamagishi J, Kawashima H, Matsuo N, Ohue M, Yamayoshi M, Fukui T . Mutational analysis of structure--activity relationships in human tumor necrosis factor-alpha. Protein Eng. 1990; 3(8):713-9. DOI: 10.1093/protein/3.8.713. View

12.

Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View

13.

Shortle D, Nathans D . Local mutagenesis: a method for generating viral mutants with base substitutions in preselected regions of the viral genome. Proc Natl Acad Sci U S A. 1978; 75(5):2170-4. PMC: 392513. DOI: 10.1073/pnas.75.5.2170. View

14.

Gray P, Aggarwal B, Benton C, Bringman T, Henzel W, Jarrett J . Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature. 1984; 312(5996):721-4. DOI: 10.1038/312721a0. View

15.

Eck M, Sprang S . The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. J Biol Chem. 1989; 264(29):17595-605. DOI: 10.2210/pdb1tnf/pdb. View

16.

Kramer W, Drutsa V, Jansen H, Kramer B, PFLUGFELDER M, Fritz H . The gapped duplex DNA approach to oligonucleotide-directed mutation construction. Nucleic Acids Res. 1984; 12(24):9441-56. PMC: 320472. DOI: 10.1093/nar/12.24.9441. View

17.

Wingfield P, Pain R, Craig S . Tumour necrosis factor is a compact trimer. FEBS Lett. 1987; 211(2):179-84. DOI: 10.1016/0014-5793(87)81432-1. View

18.

Carlino J, Lin L, Creasey A . Use of a sensitive receptor binding assay to discriminate between full-length and truncated human recombinant tumor necrosis factor proteins. J Biol Chem. 1987; 262(3):958-61. View

19.

Creasey A, Yamamoto R, Vitt C . A high molecular weight component of the human tumor necrosis factor receptor is associated with cytotoxicity. Proc Natl Acad Sci U S A. 1987; 84(10):3293-7. PMC: 304855. DOI: 10.1073/pnas.84.10.3293. View

20.

Fiers W, Brouckaert P, Devos R, Fransen L, Leroux-Roels G, Remaut E . Lymphokines and monokines in anti-cancer therapy. Cold Spring Harb Symp Quant Biol. 1986; 51 Pt 1:587-95. DOI: 10.1101/sqb.1986.051.01.071. View